NICE have now published their guidance on testing for Lynch syndrome, which recommends testing the tumours of all people diagnosed with bowel cancer and was principally informed by our research at PenTAG.1-3
The news has been published in the BMJ4 and has already attracted comment (see response in the article).
The NICE guidance includes information to support the NHS in adopting the recommendations.
My previous blog post (about the draft guidance) gives more detailed background on this area, and the final guidance appears to be very similar to the draft guidance.
- Snowsill T, Coelho H, Huxley N, Jones-Hughes T, Briscoe S, Frayling I, Hyde C. Molecular testing for Lynch syndrome in people with colorectal cancer: systematic reviews and economic evaluation. Health Technol Assess (In Press).
- Snowsill T, Huxley N, Hoyle M, Jones-Hughes T, Coelho H, Cooper C, Frayling I, Hyde C. A model-based assessment of the cost-utility of strategies to identify Lynch syndrome in early-onset colorectal cancer patients. BMC Cancer 2015; 15(313)
- Snowsill T, Huxley N, Hoyle M, Jones-Hughes T, Coelho H, Cooper C, Frayling I, Hyde C. A systematic review and economic evaluation of diagnostic strategies for Lynch syndrome. Health Technol Assess 2014; 18(58)
- Gulland A. All patients with colorectal cancer should be tested for genetic condition, NICE advises. BMJ 2017; 356:j998